Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

DNA hunt for why some women face early menopause

NCT ID NCT07587853

Knowledge-focused Sponsor: Abdurrahman Hamdi İnan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to find genetic reasons why some women lose ovarian function before age 40, a condition called premature ovarian insufficiency. Researchers will compare DNA from 100 women with the condition and 100 healthy women using whole exome sequencing. No drugs or treatments are given—this is purely a genetic investigation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help identify genetic markers that explain why some women experience early menopause, potentially guiding future diagnostic or treatment approaches.
What could go wrong
This is an observational study with no treatment being tested. It may not find clear genetic links, and any findings would need further research before they could help patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of women aged 18 to 39 years who are evaluated at the Department of Obstetrics and Gynecology/Reproductive Endocrinology clinics. The case group will include women diagnosed with idiopathic premature ovarian insufficiency, defined by spontaneous amenorrhea or marked menstrual irregularity lasting at least 4 months and elevated serum FSH levels. The control group will include age- and ethnicity-matched women with regular menstrual cycles, normal ovarian reserve findings for age, and no known history of infertility, premature ovarian insufficiency, gonadotoxic treatment, or ovarian surgery.

Ages

18 to 39 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For the idiopathic premature ovarian insufficiency group: * Women aged 18 to 39 years. * Spontaneous amenorrhea or marked menstrual irregularity lasting at least 4 months. * Serum FSH level greater than 25 IU/L. In cases of diagnostic uncertainty, FSH measurement may be repeated after 4 to 6 weeks. * Diagnosis of idiopathic premature ovarian insufficiency, with no known chromosomal abnormality, FMR1 premutation, defined syndromic genetic diagnosis, or iatrogenic cause. * Willingness to participate in the study and ability to provide written informed consent. For the control group: * Women aged 18 to 39 years. * Regular menstrual cycles. * Age-appropriate normal ovarian reserve findings, including FSH and AMH values within age-appropriate reference ranges and, when available, appropriate antral follicle count. * No known history of infertility, premature ovarian insufficiency, or early menopause. * No history of gonadotoxic treatment or ovarian surgery. * Willingness to participate in the study and ability to provide written informed consent. Exclusion Criteria: For both groups: * Known chromosomal abnormality, such as Turner syndrome or structural X chromosome abnormality. * FMR1 premutation carrier status. * Previously defined syndromic genetic diagnosis. * Active malignancy. * History of gonadotoxic chemotherapy or pelvic radiotherapy. * Iatrogenic ovarian damage or iatrogenic premature ovarian insufficiency after ovarian surgery. * Clear autoimmune, endocrine, or other clinical condition that may explain secondary amenorrhea. * Refusal to provide informed consent or request to withdraw study data. * Insufficient DNA sample quality or inability to complete genetic analysis for technical reasons. Additional exclusion criteria for the control group: * Known history of infertility, premature ovarian insufficiency, or early menopause. * Ovarian reserve findings below the expected range for age. * Previous gonadotoxic treatment or ovarian surgery.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Premature ovarian insufficiency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

primary ovarian failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Premature ovarian insufficiency

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Health Sciences Tepecik Training and Research Hospital, Department of Obstetrics and Gynecology

    Bornova, İzmir, 35100, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.